Buy Lumakras | Lumykras in India — Price & Availability

What is Lumakras / Lumykras used for?

Lumakras (sotorasib) is an oral KRAS G12C inhibitor. It forms an irreversible, covalent bond with the cysteine of the mutated KRAS G12C protein, locking it in an inactive state and blocking the downstream signalling that drives tumour growth, without affecting normal (wild-type) KRAS.

It is approved for adults whose tumours carry a KRAS G12C mutation, as confirmed by an approved test:

• KRAS G12C-mutated non-small cell lung cancer (NSCLC) — locally advanced or metastatic disease, in patients who have received at least one prior systemic therapy. (This NSCLC indication was granted under accelerated approval based on overall response rate and duration of response.)
• KRAS G12C-mutated metastatic colorectal cancer (mCRC) — in combination with panitumumab, in adults who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

The presence of a KRAS G12C mutation must be confirmed before treatment begins. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:

The recommended dose of Lumakras is 960 mg taken orally once daily (three 320 mg tablets, or four 240 mg tablets, or eight 120 mg tablets), with or without food, continued until disease progression or unacceptable toxicity.

• Tablets are swallowed whole; for patients who have difficulty swallowing, they may be dispersed in non-carbonated, room-temperature water as described in the prescribing information.
• If a dose is missed by more than 6 hours, or if vomiting occurs after a dose, the patient should not take an extra dose and should resume the normal schedule the next day.
  If side effects occur, the dose may be reduced in steps (a maximum of two dose reductions); the minimum dose is 240 mg once daily, and treatment is stopped if this cannot be tolerated.
• For metastatic colorectal cancer, Lumakras 960 mg once daily is used together with panitumumab given by intravenous infusion every 2 weeks, per the panitumumab prescribing information.

The treating oncologist always determines the exact dose and any modifications.

Boxed Warning: Lumakras can cause increased liver enzymes (ALT/AST) and, in some cases, drug-induced liver injury or hepatitis. Liver function is tested before and during treatment, and the dose may be withheld, reduced, or stopped based on the results. In NSCLC patients on single-agent Lumakras 960 mg, hepatotoxicity occurred in about 27% of patients, of which about 16% were Grade 3 or higher.

• Interstitial lung disease (ILD) / pneumonitis: can be serious; report new or worsening cough, shortness of breath, or fever promptly, as treatment may need to be interrupted or stopped.
• Drug interactions: Lumakras solubility is pH-dependent, so acid-reducing medicines (proton pump inhibitors, H2 blockers, and locally acting antacids) should generally be avoided as they can lower sotorasib levels. It also interacts with certain CYP3A4 substrates/inducers and P-gp substrates — share a full medication list with the treating team.
• Pregnancy and breastfeeding: sotorasib may harm an unborn baby; effective contraception is advised, and breastfeeding is not recommended during treatment and for a period after the last dose.

Common side effects:
Frequently reported effects with single-agent Lumakras include diarrhoea, musculoskeletal pain, nausea, fatigue, liver-enzyme changes, and cough. When used with panitumumab for colorectal cancer, common effects include rash, dry skin, diarrhoea, mouth sores (stomatitis), fatigue, and musculoskeletal pain. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Lumakras through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
  Import & delivery — Lumakras is sourced and shipped under validated, temperature-controlled conditions to the patient or treating hospital.

Documents required to import Lumakras

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including KRAS G12C mutation test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Lumakras is not sold on the open market in India, there is no fixed MRP. The Lumakras cost in India depends on a few factors at the time of import:

• The number of tablets and the pack size required per cycle, which is based on the prescribed daily dose (the standard dose is 960 mg once daily).
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Lumakras cost, logistics, and delivery timeline once a valid prescription is shared. Request your Lumakras quote →

Lumakras is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Lumakras from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. Lumakras tablets are stored at room temperature, 20 °C to 25 °C (68 °F to 77 °F), with brief excursions permitted between 15 °C and 30 °C, in the original packaging. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Lumakras can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:

Lumakras first received US FDA approval on 28 May 2021 (accelerated approval) for KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy. On 16 January 2025, the FDA approved Lumakras in combination with panitumumab (Vectibix) for KRAS G12C-mutated metastatic colorectal cancer after prior chemotherapy. In the European Union, it was granted a conditional marketing authorisation in January 2022 under the brand name Lumykras for KRAS G12C-mutated advanced NSCLC. It is approved in several markets, including the United States, the European Union, Canada, Japan, and others. As of the current publicly available information, Lumakras/Lumykras is not commercially marketed in India, which is why the Named Patient route is used.